A photo of Gary Lewis McPhail.

Gary Lewis McPhail, MD


  • Clinical Medical Director, Pulmonary Ambulatory Services, Division of Pulmonary Medicine
  • Director, Cystic Fibrosis Research TDC Site, Division of Pulmonary Medicine
  • Professor, UC Department of Pediatrics
I provide family-centered and personalized care options to help children with medical concerns. Each child is unique, and families deserve choices. They are true partners in their child's care.

About

Biography

As a lung doctor (pulmonologist), I treat children and adolescents who have cystic fibrosis and chest wall disorders. I’m also a sleep medicine specialist, and I treat patients who have many types of sleep disorders.

I was drawn to my area of medicine by the great mentors I had in pediatric pulmonology, both in medical school and residency. Pediatric pulmonology provides the opportunity to do research, procedures, inpatient care and outpatient care. In addition, working with children and families is amazing and very rewarding.

My training in pediatric pulmonology and sleep medicine allows me to provide care for a wide range of childhood breathing concerns. We have clinics available at multiple Cincinnati Children's outpatient campuses, and we also serve patients via telemedicine. I enjoy doing telemedicine visits, since it allows me to learn new technology while providing convenience for families.

I provide family-centered and personalized care options to help children with medical concerns. Each child is unique, and families deserve choices. They are true partners in their child's care.

In 2016, I was honored to win the HOPE Award for Provider of Excellence from Department of Orthopaedics for my work in the Chest Wall Disorders Clinic. From 2014 to 2016, I was named one of Cincinnati Magazine's Top Doctors.

I direct cystic fibrosis clinical trials, with a focus on therapeutic trials of CFTR modulators that improve function of the cystic fibrosis protein in patients. Mutations in the CFTR gene inhibit it from performing its function, and can result in cystic fibrosis.

In my free time, my six children keep me busy.

Locations (2)

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information

Publications

Pharmacokinetic modelling to predict risk of ototoxicity with intravenous tobramycin treatment in cystic fibrosis. Dong, M; Rodriguez, AV; Blankenship, CA; McPhail, G; Vinks, AA; Hunter, LL. Journal of Antimicrobial Chemotherapy. 2021; 76:2923-2931.

33: Hypertonic saline withdraw in CF patients while on ivacaftor: An analysis of the CF Foundation Patient Registry (CFFPR). Huang, B; Chen, C; McPhail, G; Hayes, D; Wang, Z; Clancy, J; Szczesniak, R. Journal of Cystic Fibrosis. 2021; 20.

34: Predicting declines in lung function with the U.S. CF registry: Impact of initiating highly effective modulator therapy. Zhou, G; Wang, Z; Palipana, A; Andrinopoulou, E; Afonso, P; McPhail, G; Clancy, J; Gecili, E; Szczesniak, R. Journal of Cystic Fibrosis. 2021; 20:s17-s18.

Functional Impacts of Aminoglycoside Treatment on Speech Perception and Extended High-Frequency Hearing Loss in a Pediatric Cystic Fibrosis Cohort. Blankenship, CM; Hunter, LL; Feeney, MP; Cox, M; Bittinger, L; Garinis, AC; Lin, L; McPhail, G; Clancy, JP. American Journal of Audiology. 2021; 30:834-853.

Patient personalized translational tools in cystic fibrosis to transform data from bench to bed-side and back. Arora, K; Yang, F; Brewington, J; McPhail, G; Cortez, AR; Sundaram, N; Ramananda, Y; Ogden, H; Helmrath, M; Clancy, JP; et al. American Journal of Physiology - Gastrointestinal and Liver Physiology. 2021; 320:G1123-G1130.

Technology-Enabled Health Care Collaboration in Pediatric Chronic Illness: Pre-Post Interventional Study for Feasibility, Acceptability, and Clinical Impact of an Electronic Health Record-Linked Platform for Patient-Clinician Partnership. Opipari-Arrigan, L; Dykes, DM H; Saeed, SA; Thakkar, S; Burns, L; Chini, BA; McPhail, GL; Eslick, I; Margolis, PA; Kaplan, HC. JMIR mHealth and uHealth. 2020; 8.

Characterization of tracheobronchomalacia in infants with hypophosphatasia. Padidela, R; Yates, R; Benscoter, D; McPhail, G; Chan, E; Nichani, J; Mughal, MZ; Myer, C; Narayan, O; Nissenbaum, C; et al. Orphanet Journal of Rare Diseases. 2020; 15.

Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Ratjen, F; Davis, SD; Stanojevic, S; Kronmal, RA; Hinckley Stukovsky, KD; Jorgensen, N; Rosenfeld, M; Kerby, G; Kopecky, C; Anthony, M; et al. The Lancet Respiratory Medicine. 2019; 7:802-809.

Improving Detection of Rapid Cystic Fibrosis Disease Progression-Early Translation of a Predictive Algorithm Into a Point-of-Care Tool. Szczesniak, RD; Brokamp, C; Su, W; Mcphail, GL; Pestian, J; Clancy, JP. IEEE Journal of Translational Engineering in Health and Medicine. 2019; 7.

Use and Incidence of Adverse Effects of Proton Pump Inhibitors in Patients with Cystic Fibrosis. McCrory, BE; Harper, HN; McPhail, GL. Pharmacotherapy. 2018; 38:725-729.

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey